Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologic or cytologic diagnosis of a malignant neoplasm (solid tumor) arising from
any primary site with the exception of bone marrow or lymphoid tissue

- Recurrent or progressive disease after chemotherapy or radiotherapy

- Chemotherapy or radiotherapy-naive disease allowed if patient is not a candidate
for standard treatment either due to comorbidities or lack of willingness to
undergo standard treatment

- Measurable disease

PATIENT CHARACTERISTICS:

- ECOG performance status 0-2

- Absolute neutrophil count ≥ 1,500/mm^3

- Platelet count ≥ 100,000/mm^3

- Creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 30 mL/min

- Bilirubin ≤ 2 mg/dL

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No active concurrent invasive malignancy

- No peripheral neuropathy ≥ grade 2 within the past 14 days

- No hypersensitivity to bortezomib, boron, mannitol, any of the cyclooxygenase (COX-2)
inhibitors, sulfa drugs, or other nonsteroidal anti-inflammatory drugs (NSAIDs)

- No active gastrointestinal (GI) ulcers OR history of GI bleeding resulting from prior
therapy with NSAIDs

PRIOR CONCURRENT THERAPY:

- At least 2 weeks since completion of prior radiotherapy

- No prior bortezomib

- No other concurrent investigational agents

- No concurrent chemotherapy, radiotherapy, or anticancer surgery

- No concurrent immune-enhancing therapy